These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18154144)

  • 1. [Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
    Demidova TIu; Erokhina EN
    Ter Arkh; 2007; 79(10):39-45. PubMed ID: 18154144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone reduces blood pressure in non-dipping diabetic patients.
    Negro R; Dazzi D; Hassan H; Pezzarossa A
    Minerva Endocrinol; 2004 Mar; 29(1):11-7. PubMed ID: 15258553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of combined treatment with rosiglitazone and intermediate-acting insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus].
    Kandalintseva OA; Ametov AS
    Ter Arkh; 2008; 80(12):40-4. PubMed ID: 19227906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].
    Balabolkin MI; Mamaeva GG; Klebanova EM; Kuzin AG; Tel'nova ME; Kreminskaia VM
    Ter Arkh; 2008; 80(10):21-6. PubMed ID: 19105408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone and metformin.
    Hill NR; Matthews DR
    Drugs Today (Barc); 2007 Jul; 43(7):443-54. PubMed ID: 17728845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus].
    Statsenko ME; Derevianchenko MV; Pastukhova OR
    Kardiologiia; 2014; 54(11):20-4. PubMed ID: 25902654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Ter Arkh; 2010; 82(8):34-41. PubMed ID: 20873243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 12. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

  • 17. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Dangelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Cicero AF
    J Int Med Res; 2006; 34(5):545-55. PubMed ID: 17133785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.